Sucampo Pharma (SCMP) Misses Q3 EPS by 1c; Boosts FY14 Earnings Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Sucampo Announces Third Quarter 2014 Financial Results
November 6, 2014 6:45 AM ESTStrong Revenue and Sales Growth for AMITIZA
Raises 2014 Earnings Guidance, Excluding Special Items
CEO Peter Greenleaf to Provide Update on Significant Progress Against Strategic Plan
Sucampo to host conference call today at 8:30 am Eastern
BETHESDA, Md., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq: SCMP) today reported consolidated financial results for the third quarter and nine months ended September 30, 2014. Sucampo... More
